COST-EFFECTIVENESS EVALUATION OF PHID-CV VERSUS PCV-13 IN SLOVAKIA
Author(s)
Psota M1, Hlavinkova L2, Ondrusova M1, Besinova N2
1Pharm-In Ltd, Bratislava, Slovak Republic, 2GSK, Bratislava, Slovakia
Presentation Documents
OBJECTIVES: The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) have been successfully used in the Slovak national universal mass vaccination programme (UMV) to protect against invasive pneumococcal diseases (IPD), pneumonia and acute otitis media (AOM) since 2011. Six years after the introduction of PCV in paediatric UMV in Slovakia, we have estimated cost-effectiveness of the two vaccines. METHODS: A previously published Markov cohort model was adapted to the Slovak setting using local demographic (birth cohort n=55,602), clinical, epidemiological data and local serotype distribution. Only direct medical costs were included and costs and outcomes were discounted annually by 5%. The analysis was performed from a payer’s perspective in a lifetime horizon. Vaccine efficacy assumptions for a 2+1 schedule (at 3rd, 5th, and 11th month of age) were based on published trial data. In the base case, we used a vaccination coverage of 95.7%, as observed for PCV in UMV in 2016. Univariate and probabilistic sensitivity analyses (PSA) were carried out on key parameters. RESULTS: Under our model assumptions, both vaccines had a similar impact on IPD and pneumonia, but PHiD-CV generated a greater reduction in AOM cases compared to PCV-13 (5,938 cases). Hence, at price parity, PHiD-CV was dominant over PCV-13 since it returned 25 additional discounted quality-adjusted life years gained and saved 200,283€ (discounted) to the public payer. At the real 25% lower price of PHiD-CV compared to PCV-13 and full reimbursement of both vaccines, the cost-saving increased to €2,272,722 (discounted). In PSA, 95.4% simulations (n=500) were in the dominant quadrant. CONCLUSIONS: PHiD-CV is estimated to provide both additional health benefits and cost-savings compared to PCV-13, at price parity. From the public payer perspective, a substantial budget saving is estimated using PHiD-CV compared to PCV13 in paediatric UMV in Slovakia.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PIN59
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)